Balyasny Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-48,108
| Closed | -$8.18M | – | 3204 |
|
|
2025
Q4 | $8.18M | Sell |
48,108
-385,031
| -89% | -$59M | 0.01% | 1128 |
|
|
2025
Q3 | $57.1M | Buy |
433,139
+97,877
| +29% | +$11.7M | 0.07% | 320 |
|
|
2025
Q2 | $35.6M | Buy |
335,262
+12,751
| +4% | +$1.39M | 0.05% | 441 |
|
|
2025
Q1 | $40M | Buy |
322,511
+249,636
| +343% | +$32.6M | 0.07% | 362 |
|
|
2024
Q4 | $8.97M | Sell |
72,875
-157,457
| -68% | -$18.6M | 0.01% | 1012 |
|
|
2024
Q3 | $25.7M | Sell |
230,332
-14,345
| -6% | -$1.57M | 0.04% | 541 |
|
|
2024
Q2 | $26.1M | Buy |
244,677
+239,384
| +4,523% | +$26.3M | 0.05% | 511 |
|
|
2024
Q1 | $637K | Sell |
5,293
-195,160
| -97% | -$23.9M | ﹤0.01% | 1970 |
|
|
2023
Q4 | $24.7M | Buy |
200,453
+129,531
| +183% | +$16.2M | 0.05% | 520 |
|
|
2023
Q3 | $9.18M | Sell |
70,922
-42,007
| -37% | -$5.6M | 0.02% | 877 |
|
|
2023
Q2 | $14M | Buy |
+112,929
| New | +$15.2M | 0.03% | 649 |
|
|
2023
Q1 | – | Sell |
-163,382
| Closed | -$26M | – | 2903 |
|
|
2022
Q4 | $26M | Buy |
+163,382
| New | +$23.9M | 0.07% | 373 |
|
|
2022
Q3 | – | Sell |
-79,986
| Closed | -$12.5M | – | 3044 |
|
|
2022
Q2 | $12.5M | Sell |
79,986
-5,098
| -6% | -$785K | 0.04% | 577 |
|
|
2022
Q1 | $13.2M | Buy |
+85,084
| New | +$12.3M | 0.04% | 586 |
|
|
2021
Q3 | – | Sell |
-188,541
| Closed | -$33.5M | – | 2175 |
|
|
2021
Q2 | $33.5M | Buy |
+188,541
| New | +$32.7M | 0.16% | 157 |
|
|
2021
Q1 | – | Sell |
-216,291
| Closed | -$35.6M | – | 1921 |
|
|
2020
Q4 | $35.7M | Buy |
+216,291
| New | +$32.2M | 0.2% | 124 |
|
|
2019
Q4 | – | Sell |
-190,414
| Closed | -$24.4M | – | 1328 |
|
|
2019
Q3 | $24.4M | Buy |
190,414
+171,678
| +916% | +$23M | 0.17% | 194 |
|
|
2019
Q2 | $2.67M | Buy |
18,736
+6,383
| +52% | +$858K | 0.02% | 797 |
|
|
2019
Q1 | $1.77M | Buy |
+12,353
| New | +$1.61M | 0.01% | 860 |
|
|
2018
Q4 | – | Sell |
-58,365
| Closed | -$9.81M | – | 1560 |
|
|
2018
Q3 | $9.81M | Sell |
58,365
-40,451
| -41% | -$6.96M | 0.04% | 497 |
|
|
2018
Q2 | $17M | Sell |
98,816
-54,291
| -35% | -$8.87M | 0.08% | 349 |
|
|
2018
Q1 | $23.1M | Sell |
153,107
-112,387
| -42% | -$16.5M | 0.1% | 296 |
|
|
2017
Q4 | $35.7M | Buy |
+265,494
| New | +$36.8M | 0.11% | 238 |
|
|
2017
Q3 | – | Sell |
-270,602
| Closed | -$42.1M | – | 1982 |
|
|
2017
Q2 | $42.1M | Buy |
270,602
+164,806
| +156% | +$25.2M | 0.17% | 152 |
|
|
2017
Q1 | $15.4M | Sell |
105,796
-143,901
| -58% | -$18.7M | 0.07% | 353 |
|
|
2016
Q4 | $27.2M | Sell |
249,697
-139,933
| -36% | -$15.6M | 0.15% | 195 |
|
|
2016
Q3 | $47.3M | Buy |
389,630
+263,440
| +209% | +$35.5M | 0.27% | 120 |
|
|
2016
Q2 | $17.8M | Buy |
126,190
+49,590
| +65% | +$7.31M | 0.12% | 239 |
|
|
2016
Q1 | $10M | Buy |
+76,600
| New | +$9.53M | 0.06% | 401 |
|
|
2015
Q4 | – | Sell |
-7,011
| Closed | -$931K | – | 1333 |
|
|
2015
Q3 | $931K | Buy |
+7,011
| New | +$1.21M | 0.01% | 738 |
|
|
2014
Q3 | – | Sell |
-33,300
| Closed | -$4.89M | – | 788 |
|
|
2014
Q2 | $4.89M | Buy |
+33,300
| New | +$4.62M | 0.06% | 387 |
|
|
2013
Q4 | – | Sell |
-156,026
| Closed | -$14.3M | – | 557 |
|
|
2013
Q3 | $14.3M | Buy |
156,026
+51,874
| +50% | +$4.18M | 0.19% | 133 |
|
|
2013
Q2 | $7.16M | Buy |
+104,152
| New | +$6.37M | 0.12% | 204 |
|
Other funds holding JAZZ
VPM
VCM
EC
Balyasny Asset Management's JAZZ Position: Q1 2026 in Review
Balyasny Asset Management sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2026, closing a stake of 48,108 shares — an estimated $8.18M sold.
Balyasny Asset Management first reported a position in JAZZ in Q2 2013 and held it in 33 quarters. The position peaked at $57.1M in Q3 2025. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.
- Balyasny Asset Management reported no remaining Jazz Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- Balyasny Asset Management sold 48,108 Jazz Pharmaceuticals shares in Q1 2026, an estimated $8.18M.
- Balyasny Asset Management first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 33 quarters.
- Balyasny Asset Management's Jazz Pharmaceuticals position peaked at $57.1M in Q3 2025.
- 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.
Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.